IBS
Also called irritable bowel syndrome, spastic colon.
By Dr Chad Okay3 min read
IBS stands for irritable bowel syndrome. It is a long-term gut condition that causes recurring abdominal pain alongside altered bowel habits, without visible damage to the gut. NICE estimates it affects roughly 1 in 10 to 1 in 5 UK adults. The cause is not single. It involves gut motility, gut sensitivity, the microbiome, the nervous system, and how the brain processes gut signals.
The three subtypes
- IBS-D: diarrhoea-predominant. Loose stools more than 25% of the time, hard stools less than 25%.
- IBS-C: constipation-predominant. Hard stools more than 25% of the time, loose stools less than 25%.
- IBS-M: mixed. Both loose and hard stools more than 25% of the time. The most variable subtype to manage.
How IBS is diagnosed
IBS is diagnosed using clinical history, not by a positive test. The current Rome IV criteria require recurrent abdominal pain at least one day a week in the last three months, alongside two or more of: pain related to defaecation, change in stool frequency, or change in stool form. NICE in the UK recommends ruling out coeliac disease (with a blood test) and inflammatory bowel disease (often with faecal calprotectin) before settling on IBS.
Common triggers
- FODMAPs. Wheat, onion, garlic, lactose, apples, pears, beans, mushrooms.
- Stress and anxiety. The gut-brain axis is heavily involved.
- Hormonal cycle changes. Symptoms often worsen in the premenstrual and menstrual phase.
- Caffeine and alcohol.
- Disrupted sleep, especially shift work patterns.
- Some food poisoning episodes can trigger post-infectious IBS that lasts months or years.
First-line management in the UK
NICE Clinical Guideline 61 sets out the standard pathway. It starts with general dietary and lifestyle changes: regular meals, slower eating, adequate fluid, limited caffeine and alcohol, and adjusting fibre intake. If symptoms persist, the second-line dietary intervention is a low-FODMAP diet under a registered dietitian. Antispasmodics like mebeverine, peppermint oil capsules, and bowel-specific laxatives (for IBS-C) or low-dose loperamide (for IBS-D) are common medications. Cognitive behavioural therapy and gut-directed hypnotherapy have evidence and are recommended by NICE for refractory IBS, where symptoms have not responded to medication after 12 months.
Newer options
Linaclotide is a UK-licensed drug for moderate-to-severe IBS-C. Eluxadoline was licensed for IBS-D but its UK marketing authorisation has since been withdrawn. Rifaximin, an antibiotic that stays largely in the gut, is sometimes used in IBS-D where SIBO is suspected. Specific probiotic strains have evidence for some IBS subtypes. Continuous food and symptom tracking, including with wearables, is a developing area of research.
When the symptoms are not IBS
Some signs are not consistent with IBS and need a doctor urgently: blood in stool, unintentional weight loss, persistent night-time symptoms that wake you up, persistent fever, anaemia, or a strong family history of bowel cancer. NHS guidance is to see a doctor without delay if any of these are present.
Common questions
IBS is a functional condition. The gut behaves abnormally but does not show damage on imaging or biopsy. IBD (Crohn's disease, ulcerative colitis) involves visible inflammation and tissue damage. IBD is typically diagnosed with colonoscopy and biopsies. The two can co-exist.
Sources
- 1NICE Clinical Guideline 61: irritable bowel syndrome in adults, diagnosis and managementNICE
- 2NICE CG61: introduction (UK prevalence 10-20%)NICE
- 3Rome IV diagnostic criteria for IBSRome Foundation
- 4Symptoms of IBS, when to see a doctorNHS
- 5NICE DG11/HTG320: faecal calprotectin tests to distinguish IBD from IBSNICE
- 6Constella (linaclotide) 290 micrograms hard capsules, SmPC (indication: moderate to severe IBS-C in adults)electronic medicines compendium (emc)
- 7NICE TA471: eluxadoline for IBS-D, withdrawn guidanceNICE
- 8Alammar et al, systematic review and meta-analysis: efficacy of peppermint oil in IBSPubMed
- 9Staudacher et al 2011: low-FODMAP vs standard dietary advice in IBS (76% satisfaction)PubMed
- 10Klem et al 2017, meta-analysis: prevalence, risk factors and outcomes of IBS after infectious enteritisGastroenterology (PMC)
- 11Mulak et al 2014: symptomatology of IBS and IBD during the menstrual cycleGastroenterology Report (PMC)
- 12Pannemans & Corsetti: eluxadoline review (mechanism, rifaximin minimally absorbed)Therapeutic Advances in Gastroenterology (PMC)



